Oncotelic Therapeutics Inc. (OTLC) Champions Targeted RNA Therapy for Underserved Cancers

• On the global stage, the Cancer Atlas estimates a dramatic rise in cancer cases, adding urgency to the need for therapeutic innovation
• Oncotelic’s mission focuses on developing first-in-class RNA therapeutics and small-molecule drugs to serve high-unmet-need cancers and rare pediatric diseases
• This year, the company achieved a major milestone by successfully completing a phase 1 clinical trial evaluating OT-101 combining Interleukin-2

In a landscape where cancer and underserved diseases continue to devastate millions, the demand for groundbreaking RNA-based, immunotherapeutic, and targeted treatments has never been more urgent. Oncotelic Therapeutics (OTCQB: OTLC) is answering this call with pioneering RNA candidates and strategic programs aimed at some of the most lethal and overlooked cancers.

The global cancer burden is both vast and growing. In the United States alone, an estimated 2,041,910 new cancer cases and 618,120 cancer-related deaths are projected for 2025, including conditions such as lung, breast, prostate and colorectal cancers that dominate incidence and mortality statistics (ibn.fm/M7MFi). On the global stage, the Cancer Atlas estimates a dramatic rise in cancer cases, from 20 million new cases in 2022 to an anticipated 35 million by 2050, adding urgency to the need for therapeutic innovation (ibn.fm/D6Vs8). The scale of these figures underlines the importance of developing more effective, accessible treatments for both common and rare forms of cancer.

Immunotherapy and RNA-based approaches have begun to reshape the understanding of cancer treatment. The FDA approved 17 new immunotherapies in 2024 alone, spanning multiple cancer types and delivering breakthroughs such as checkpoint inhibitors and individualized vaccines (ibn.fm/KuJTN). Yet despite this progress, significant unmet needs persist, particularly in rare pediatric cancers, resistant solid tumors and underserved population. Oncotelic is strategically positioned to fill gaps where traditional treatments fall short.

Oncotelic’s mission focuses on developing first-in-class RNA therapeutics and small-molecule drugs to serve high-unmet-need cancers and rare pediatric diseases (ibn.fm/rBiPA). Its lead candidate, OT-101, is a pioneering anti-TGF-β RNA therapeutic that has demonstrated single-agent activity in relapsed and refractory cancers (ibn.fm/gW9iN). OT-101 also exhibits activity against SARS-CoV-2, underscoring its versatile potential. Importantly, OT-101 has received rare pediatric designations for aggressive diseases such as diffuse intrinsic pontine glioma (“DIPG”), melanoma (via CA4P) and acute myeloid leukemia (via OXi4503), highlighting the company’s focus on underserved populations.

This year, Oncotelic achieved a major milestone by successfully completing a phase 1 clinical trial evaluating OT-101 in combination with Interleukin-2 in patients with advanced or metastatic solid tumors (ibn.fm/fj4eM). The trial demonstrated a favorable safety and tolerability profile, clearing the way for next-stage efficacy trials, which may include combinations with checkpoint inhibitors for cancers like lung, melanoma, and colorectal disease.

Beyond its clinical assets, Oncotelic’s strategic breadth is bolstered by a robust intellectual property foundation and expansion via joint ventures. The company currently holds 45% ownership of GMP Bio, a joint venture that advances nanomedicine pipeline under the leadership of CEO Dr. Vuong Trieu (ibn.fm/65vo6). Trieu’s leadership extends to a portfolio that includes more than 500 patent applications and 75 issued U.S. patents centered on tumor microenvironment biology and drug delivery innovations (ibn.fm/9DoDS).

Oncotelic isn’t just developing drugs; the company is constructing a biotech ecosystem capable of delivering personalized, effective treatments for diseases that remain largely untreated. Its pipeline spans from RNA-based immuno-oncology to small-molecule repositioning and extends into rare pediatric indications, positioning the company as a diversified innovator. The success of OT-101’s clinical trajectory, combined with GMP Bio’s emerging nanomedicine pipeline and Trieu’s IP legacy, forms a compelling platform for future growth and therapeutic breakthroughs.

For more information, visit the company’s website at www.Oncotelic.com.

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at ibn.fm/OTLC

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN